Profile data is unavailable for this security.
About the company
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
- Revenue in USD (TTM)276.98m
- Net income in USD-59.50m
- Incorporated2009
- Employees619.00
- LocationAdaptive Biotechnologies Corp1165 Eastlake Ave ESEATTLE 98109United StatesUSA
- Phone+1 (206) 659-0067
- Fax+1 (206) 659-0667
- Websitehttps://www.adaptivebiotech.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Disc Medicine Inc | 0.00 | -181.11m | 2.11bn | 84.00 | -- | 3.42 | -- | -- | -5.35 | -5.35 | 0.00 | 16.38 | 0.00 | -- | -- | 0.00 | -32.18 | -- | -33.75 | -- | -- | -- | -- | -- | -- | -- | 0.0481 | -- | -- | -- | -43.08 | -- | -- | -- |
| Mineralys Therapeutics Inc | 0.00 | -171.36m | 2.18bn | 51.00 | -- | 3.78 | -- | -- | -2.96 | -2.96 | 0.00 | 7.30 | 0.00 | -- | -- | 0.00 | -39.48 | -- | -42.14 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -147.31 | -- | -- | -- |
| Maze Therapeutics Inc | 0.00 | -101.46m | 2.21bn | 125.00 | -- | 5.83 | -- | -- | -2.68 | -2.68 | 0.00 | 7.89 | 0.00 | -- | -- | 0.00 | -41.05 | -- | -43.88 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 103.39 | -- | -- | -- |
| Wave Life Sciences Ltd | 109.23m | -121.95m | 2.32bn | 287.00 | -- | 16.32 | -- | 21.21 | -0.7363 | -0.7363 | 0.6661 | 0.8262 | 0.3642 | -- | 21.85 | 380,592.30 | -40.66 | -48.01 | -71.05 | -88.09 | -- | -- | -111.64 | -205.56 | -- | -- | 0.00 | -- | -4.42 | 46.62 | -68.67 | -- | -24.87 | -- |
| Arcus Biosciences Inc | 240.00m | -341.00m | 2.32bn | 627.00 | -- | 4.65 | -- | 9.69 | -3.43 | -3.43 | 2.38 | 4.07 | 0.2156 | -- | 13.71 | 382,775.10 | -30.64 | -16.91 | -38.40 | -19.76 | -- | -- | -142.08 | -97.85 | -- | -- | 0.1835 | -- | 120.51 | 76.65 | 7.82 | -- | 25.53 | -- |
| Immunome Inc | 9.68m | -222.74m | 2.44bn | 118.00 | -- | 7.70 | -- | 252.60 | -2.95 | -2.95 | 0.122 | 2.88 | 0.0348 | -- | -- | 82,025.42 | -80.08 | -120.50 | -91.80 | -146.20 | -- | -- | -2,301.30 | -2,078.20 | -- | -- | 0.00 | -- | -35.50 | -- | -174.29 | -- | 196.63 | -- |
| Adaptive Biotechnologies Corp | 276.98m | -59.50m | 2.47bn | 619.00 | -- | 11.27 | -- | 8.91 | -0.3987 | -0.3987 | 1.79 | 1.42 | 0.5265 | 7.82 | 6.01 | -- | -11.30 | -22.45 | -13.86 | -25.94 | 74.24 | 66.23 | -21.47 | -88.21 | 3.23 | -24.47 | 0.3684 | -- | 54.77 | 23.00 | 62.69 | -- | -- | -- |
| Travere Therapeutics Inc | 435.83m | -88.54m | 2.49bn | 385.00 | -- | 33.83 | -- | 5.71 | -1.08 | -1.08 | 4.80 | 0.8223 | 0.8357 | 1.74 | 8.06 | 1,132,018.00 | -16.98 | -41.64 | -24.67 | -51.97 | 97.63 | 95.90 | -20.32 | -175.36 | 2.71 | -- | 0.8089 | -- | 60.55 | 5.87 | 14.80 | -- | 45.42 | -- |
| Dyne Therapeutics Inc | 0.00 | -423.80m | 2.51bn | 240.00 | -- | 3.20 | -- | -- | -3.66 | -3.66 | 0.00 | 4.85 | 0.00 | -- | -- | 0.00 | -51.81 | -57.98 | -55.30 | -63.58 | -- | -- | -- | -- | -- | -- | 0.1254 | -- | -- | -- | -34.54 | -- | 7.60 | -- |
| Ideaya Biosciences Inc | 214.83m | -160.74m | 2.65bn | 131.00 | -- | 2.43 | -- | 12.35 | -1.85 | -1.85 | 2.43 | 12.46 | 0.1772 | -- | -- | 1,639,954.00 | -13.26 | -22.71 | -13.86 | -24.48 | -- | -- | -74.82 | -411.78 | -- | -- | 0.00 | -- | -70.07 | -- | -142.98 | -- | 23.31 | -- |
| Viridian Therapeutics Inc | 70.79m | -301.97m | 2.66bn | 143.00 | -- | 7.30 | -- | 37.62 | -3.72 | -3.72 | 0.8716 | 6.12 | 0.105 | -- | 2.02 | 495,028.00 | -44.77 | -50.26 | -48.05 | -53.97 | -- | -- | -426.58 | -12,930.56 | -- | -- | 0.0399 | -- | -3.82 | -41.64 | -13.55 | -- | 43.49 | -- |
| Veracyte Inc | 495.14m | 30.32m | 2.83bn | 824.00 | 94.36 | 2.25 | 53.67 | 5.71 | 0.3791 | 0.3791 | 6.21 | 15.91 | 0.3747 | 7.66 | 10.25 | 600,899.30 | 2.29 | -4.19 | 2.43 | -4.43 | 68.53 | 66.82 | 6.12 | -13.70 | 5.94 | -- | 0.00 | -- | 23.46 | 29.93 | 132.44 | -- | 32.57 | -- |
| Beam Therapeutics Inc | 55.70m | -414.64m | 2.83bn | 483.00 | -- | 2.93 | -- | 50.86 | -4.43 | -4.43 | 0.5936 | 9.53 | 0.0449 | -- | -- | 115,323.00 | -33.41 | -24.98 | -38.87 | -29.69 | -- | -- | -744.41 | -241.53 | -- | -- | 0.00 | -- | -83.18 | 412.30 | -184.28 | -- | -6.50 | -- |
| Spyre Therapeutics Inc | 0.00 | -148.97m | 2.84bn | 95.00 | -- | 7.40 | -- | -- | -2.55 | -2.55 | 0.00 | 7.53 | 0.00 | -- | -- | 0.00 | -32.19 | -75.44 | -36.25 | -85.33 | -- | -- | -- | -3,540.66 | -- | -- | 0.00 | -- | -100.00 | -- | 38.60 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Adaptive Biotechnologies Corp's reporting currency: US Dollar USD
50.63%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Viking Global Investors LPas of 30 Sep 2025 | 29.99m | 19.65% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 11.08m | 7.26% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 10.27m | 6.72% |
| Columbia Management Investment Advisers LLCas of 30 Sep 2025 | 5.97m | 3.91% |
| Westfield Capital Management Co. LPas of 31 Dec 2025 | 4.06m | 2.66% |
| Geode Capital Management LLCas of 31 Dec 2025 | 3.51m | 2.30% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 3.18m | 2.08% |
| Aristotle Atlantic Partners LLCas of 30 Sep 2025 | 3.13m | 2.05% |
| Lord, Abbett & Co. LLCas of 31 Dec 2025 | 3.08m | 2.02% |
| Driehaus Capital Management LLCas of 30 Sep 2025 | 3.02m | 1.98% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
